Cellceutix Corp. develops small molecule therapies for treatment of cancer, autism and inflammatory disease. The company is supported by a panel of officers and advisors with extensive experience and knowledge in the fields of cancer and genetics, as well as with wide experience in the pharmaceutical business and relative researching, developing and marketing.
Most of the company’s efforts center on the company’s lead product Kevetrin, which is in development for drug-resistant cancers. Cellceutix is concluding final studies before applying for FDA approval for human studies. The company’s focus is maintained by a strong management team and a shared commitment to develop treatments for today’s most challenging diseases.
Cellceutix is headed by chairman of the board and CEO George W. Evans, JD, MBA. Mr. Evans has worked in the pharmaceutical industry for more than 25 years, including several senior executive positions for Pfizer Inc. (NYSE: PFE) as general counsel for Pfizer’s global prescription drug unit, and a member of the unit’s leadership team. Mr. Evans’ experience spans a wide range of aspects in the pharmaceutical industry, including early-stage research to end-of-life cycle strategies and involvement in several mergers and acquisitions.
Dr. Krishna Menon, PhD, VMD, serves as Cellceutix’s president, chief scientific officer, and member of the company’s board of directors. Dr. Menon has more than 25 years of experience in drug development for academia and industry. As a veterinarian surgeon, Dr. Menon’s career started with his role as senior government veterinarian for a major parish in Jamaica. For two years he was director of agriculture for the Cayman Islands in the British Caribbean. Dr. Menon’s previous work includes anti-folate therapies for various cancers, research associate at Harvard University, and research scientist at In Vivo Research. After operating his own veterinary oncology and drug development consultancy practice, Dr. Menon served as group leader for Cancer In Vivo Research and Clinical Development for Eli Lilly & Co. (NYSE: LLY) where he was lead researcher for the blockbuster drugs Alimta and Gemzar.
Leo Ehrlich, CPA, has served as Cellceutix CFO since June 2007, and currently serves on the company’s board of directors. Mr. Ehrlich was previously director at StatSureDiagnostic Systems Inc., and has held various executive positions for large corporations including being a founder of NanoViricides in which his tenure saw the price per share rise from $.10 to $4.00.
For more information visit http://www.cellceutix.com.
Let us hear your thoughts: Cellceutix Corp. Message Board